Max-Planck-Gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Boehringer Mannheim Gmbh

Other

Wilex Biotechnology Gmbh

Bayer Cropscience Ag

Seemann Sub Gmbh & Co. Kg

Freie Universitat Berlin

Robert Huber

Wolfram Bode

Uwe Jacob

Luis Moroder

Peter Sondermann

Erhard Kopetzki

Richard Engh

Karl-Peter Hopfner

Olaf G Wilhelm

Thomas Martin

Viktor Magdolen

Stefan Sperl

Josef Stadlwieser

Wolf-R&uuml;diger Ulrich

Joerg Stuerzebecher

Thomas B&auml;r

Ulrich Thibaut

Rolf Beume

Christian Sommerhoff

Norbert Schaschke

Nuria Arroyo De Prada

Andreas Bergner

Pedro Jose Barbosa Pereira

Andreas Dominik

Karl-Josef Goebel

Daniela Bundschuh

Peter Helmut Schreier

Ronald Ebbert

Christian Aichinger

Reiner Kiefersauer

Kerstin Wendt

Robert Stoss

Michael Groll

Cosimo Damiano Cadicamo

Beate Koksch

Elisabeth Ruge

Hans Christian Korting

Chiara Cabrele

Hans Dieter Höltje

Cabrele Chiara

The invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either Fc&#x3b3;RIIb or Fc&#x3b3;RIIa.

Substance binding human IgG Fc receptor IIb (Fc&#x3b3;RIIb)

Recombinant soluble Fc receptors according to the present invention are characterized by the absence of transmembrane domains, signal peptides and glycoslyation. Such Fc receptors can easily be obtained by expressing respective nucleic acids in prokaryotic host ells and renaturation of the obtained inclusion bodies, which procedure leads to a very homogenous and pure product. The products can be used for diagnostic as well as pharmaceutical applications and also for the generation of crystal structure data. Such crystal structure data can be used for the modeling of artificial molecules. A further embodiment comprises coupling the Fc receptors according to the invention to solid materials like chromatography materials that an be used to separate and/or enrich antibodies.

Recombinant soluble FC receptors

The present invention relates to methods for identifying fungicides and also inhibitors of the 20S and 26S proteasomes, to methods for isolating 20S proteasomes, to the use of 20S proteasomes for identifying fungicides and to the use of the inhibitors of 26S and/or 20S proteasomes as fungicides.

Methods for identifying inhibitors of the 20S and 26S proteasome

Recombinant soluble Fc receptors according to the present invention are characterized by the absence of transmembrane domains, signal peptides and glycosylation. Such Fc receptors can easily be obtained by expressing respective nucleic acids in prokaryotic host cells and renaturation of the obtained inclusion bodies, which procedure leads to a very homogenous and pure product. The products can be used for diagnostic as well as pharmaceutical applications and also for the generation of crystal structure data. Such crystal structure data can be used for the modelling of artificial molecules. A further embodiment comprises coupling the Fc receptors according to the invention to solid materials like chromatography materials that can be used to separate and/or enrich antibodies.

Recombinant soluble Fc receptors

The invention relates to a stop valve (&#x2033;) for a portable pressurized-gas container (). A valve body () is provided with three connection adapters (), i.e. one central connection adapter as a gas tank connection adapter (), another connection adapter as outlet connection adapter () and a third connection adapter as spindle drive receiving adapter (). Valve body () is made in several parts including valve body element () with the outlet connection adapter () and a spindle drive receiving adapter () and a radial valve seat element receiving bore () going to the bottom of the spindle drive receiving adapter (). Furthermore, the valve body () has an oblong valve seat element () with gas supply bore () provided at the one end of the valve seat () and a bearing collar () on the other end. In its assembled state, the valve seat element () is inserted tightly into the radial bolt receiving bore (). In addition, the valve body () has a main bolt () which is inserted tightly into the central main bolt receiving bore (). Suitable gas supply bores () allow gas to flow from the connected pressurized-gas container () via the spindle drive receiving adapter () to the outlet connection adapter ().

Stop valve for a portable pressurized-gas container, in particular for a compressed-air bottle for diving applications

A method is described for inhibiting urokinase plasminogen activator in a human or animal patient. The method involves administering to the patient a urokinase plasminogen activator inhibiting effective amount of a compound of the formula (I): 

Highly selective inhibitors of the urokinase plasminogen activator

The invention relates to novel selective inhibitors of the urokinase plasminogen activator (uPA, EC 3.4.21.31), of the arylguanidine type.

A chimeric serine protease whose protease domain is composed of two domain halves (half-sides) with a &bgr;-folded sheet structure, wherein the first domain half corresponds to the first domain half of a first serine protease and the second domain half corresponds to the second domain half of a second serine protease, has improved properties and can be readily crystallized.

Chimeric serine proteases

Tryptase inhibitors

The invention relates to novel inhibitors of human tryptase which are used in the pharmaceutical industry for the production of medicaments.

A holding device for particulate material samples features a carrier block for a holding a capillary or a loop holder that has a free mounting end for a particular sample, whereby the carrier block includes at least one integral gas channel with an opening end that is directed at the mounting end of the holding capillary or a loop holder.

Holding device for particulate samples

A chimeric serine protease whose protease domain is composeD. of two domain halves (half-sides) with a &bgr;-folded sheet structure, wherein the first domain half corresponds to the first domain half of a first serine protease and the second domain half corresponds to the second domain half of a second serine protease, has improved properties and can be readily crystallized.

A chimeric serine protease whose protease domain is composed of two domain halves (half-sides) with a .beta.-folded sheet structure, wherein the first domain half corresponds to the first domain half of a first serine protease and the second domain half corresponds to the second domain half of a second serine protease, has improved properties and can be readily crystallized.

Growing community of inventors

Germering, Germany

Robert Huber